相关实验视频

Updated: Mar 16, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

网络药理学分析和实验验证对修饰的Taohong Siwu抗动脉样硬化的制剂进行了实验验证

Changle Shao¹, Wanting Meng¹, Ke Ning¹

¹School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

In vitro cellular & developmental biology. Animal

|March 15, 2026

概括

经过修改的Taohong Siwu蒸 (MTHSWD) 通过调节PI3K/AKT和MAPK信号通路,有效治疗动脉样硬化 (AS). 这种传统医学促进内皮存活,并减少AS小鼠模型中的血管病理.

科学领域:

传统中国医药传统中国医药
药理学药理学是一个学科.
心血管研究研究心血管研究

背景情况:

动脉样硬化 (AS) 是一种复杂的心血管疾病,具有显著的未满足治疗需求.
修改的Taohong Siwu (MTHSWD),一种传统的中医药,显示出对心血管疾病的承诺,但其抗动脉样硬化机制尚未完全理解.

研究的目的:

研究MTHSWD在治疗动脉样硬化的潜在机制.
确定关键的生物活性成分,分子点和参与MTHSWD对AS的治疗作用的信号通路.

主要方法:

在AS小鼠模型中使用MTHSWD进行治疗,并对血管病理和纤维化进行组织学分析.
网络药理学被用来识别活性成分和标,然后进行分子对接.
西方斑点分析用于关键蛋白质和通路的生物化学验证.

主要成果:

在AS小鼠模型中,MTHSWD治疗显著减少了血管异常和纤维化.
网络药理学确定了133个活性成分和191个重叠的目标,突出了AKT1和MAPK家族成员作为中央监管机构.
实验验证证了MTHSWD对AKT1,MAPK1/14,与亡相关的蛋白质 (分裂酶-3,Bcl-2) 的调节,提高了内皮活力.

结论:

通过PI3K/AKT和MAPK信号通路的多目标调制,MTHSWD具有抗动脉样硬化作用.
这种可以促进内皮细胞的存活,并抑制细胞亡,从而减轻与AS相关的血管病理.

关键词:

动脉样硬化是一种动脉样硬化.在MTHSWDWD中使用.分子对接是分子对接.网络药理学网络药理学传统的中国医学是传统的中国医学.

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...